RUTHERFORD, N.J., Jan. 29, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based diagnostics, is launching a webinar series to inform clinicians and pathologists of the value of its proprietary DNA-based test for cervical cancer, FHACT™, which is processed in the Company’s CLIA certified, clinical laboratory. The webinar series will begin on Friday, January 31, at 9:30 a.m. ET and will be available again on Thursday, February 6, at 9:30 a.m. ET.
Help employers find you! Check out all the jobs and post your resume.
